Document registry — page 24
Every document the Institute has published, 1,631 in total, with its identifier, type, certainty rating and review date.
Documents
-
Randomised, double-blind, placebo-controlled, phase 2 study of Maridebart cafraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no…
Very low12 Mar 2025 -
Are the trials in the incretin evidence network sufficiently similar to support indirect comparison?
Moderate11 Mar 2025 -
Phase 1 ascending dose, phase 1 study of Mazdutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low11 Mar 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Retatrutide compared with its…
Moderate10 Mar 2025 -
Randomised, double-blind, placebo-controlled, phase 1 study of Petrelintide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low06 Mar 2025 -
How is access to incretin-based obesity pharmacotherapy distributed, and what does the pattern of unregulated supply indicate about it?
Low05 Mar 2025 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, what is the effect of Larazotide acetate compared with the comparator used in its…
Moderate01 Mar 2025 -
Custom-synthesis peptides, SARMs, injectable oils and raw materials. 350+ catalogue lines with a custom-synthesis emphasis.
01 Mar 2025 -
Consultation on the draft monograph for GHK-Cu, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…
27 Feb 2025 -
Fixed-ratio combination of a long-acting amylin analogue and a GLP-1 receptor agonist. The combination pairs two complementary satiation mechanisms: GLP-1 receptor agonism acting on hypothalamic and hindbrain appetite…
Moderate24 Feb 2025 -
Observational study of Epithalon in ageing over multi-year. Primary result: The Institute has not been able to obtain a protocol, a randomisation procedure or an…
24 Feb 2025 -
Established atherosclerotic disease of the coronary, cerebral or peripheral arterial beds, or a risk profile sufficient for enrolment in a cardiovascular outcome trial.
23 Feb 2025 -
Randomised crossover, phase 1 study of Amycretin in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low23 Feb 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in type 2 diabetes randomising 731 participants over 48 weeks. Primary result: A dose-dependent…
Moderate22 Feb 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of BPC-157 in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary…
Very low22 Feb 2025 -
Phase 1 ascending dose, phase 1 study of Selank in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low18 Feb 2025 -
Domain-specific cognitive function or protection against cognitive decline, assessed by standardised neuropsychological batteries or clinical dementia rating.
15 Feb 2025 -
Does treatment with a glucagon-like peptide-1 receptor agonist increase residual gastric content at the time of elective procedural sedation?
Low13 Feb 2025 -
In the population defined for type 2 diabetes mellitus, is the effect of Mazdutide maintained across the full duration of the contributing trials?
Moderate13 Feb 2025 -
Phase 1 ascending dose, phase 1 study of Survodutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low13 Feb 2025 -
Event-driven kidney outcome trial, phase 3 study of Semaglutide in chronic kidney disease and type 2 diabetes randomising 3,533 participants over median 3.4 years…
High12 Feb 2025 -
Observational, phase 2 study of Survodutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low10 Feb 2025 -
Single-arm open-label, phase 3 study of Tirzepatide in hfpef and obesity over open-label extension of the parent trial. The Institute holds no reported primary result…
Very low08 Feb 2025 -
Long-acting amylin and calcitonin receptor agonist (acylated). Amylin is co-secreted with insulin and acts at the area postrema to promote meal-related satiation, and separately reduces gastric emptying and…
Moderate06 Feb 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in mash over as stated in the parent protocol. The Institute holds no reported primary result…
Very low05 Feb 2025 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Exenatide compared with its comparator?
High31 Jan 2025 -
Symptomatic heart failure with a left ventricular ejection fraction of 50 % or above, occurring with obesity as a dominant phenotypic driver.
29 Jan 2025 -
Single-arm open-label, phase 3 study of Tirzepatide in sleep apnoea and obesity over open-label extension of the parent trial. The Institute holds no reported primary…
Very low29 Jan 2025 -
Synthetic tetrapeptide. Epithalon is supplied on the premise that it activates telomerase and thereby extends replicative lifespan, on the basis of cell-culture reports of…
Very low26 Jan 2025 -
What in-use period can be supported for a reconstituted research peptide solution?
Moderate23 Jan 2025 -
Randomised crossover, phase 1 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low22 Jan 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Maridebart cafraglutide compared…
Low21 Jan 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low21 Jan 2025 -
Single-arm open-label, phase 2 study of Survodutide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low20 Jan 2025 -
Steatotic liver disease with histological evidence of hepatocyte ballooning and lobular inflammation occurring in the context of at least one cardiometabolic risk…
18 Jan 2025 -
Consultation on the draft of this intervention review, which registers the question: In adults with type 2 diabetes and chronic kidney disease, what is the effect of a…
17 Jan 2025 -
Dual GIP and GLP-1 receptor agonist (acylated). Tirzepatide engages both incretin receptors from a single molecule. GLP-1 receptor agonism reproduces the insulinotropic, glucagonostatic, gastric…
High16 Jan 2025 -
Peptides, SARMs, injectable oils and raw materials. Established life-science reagent operation.
15 Jan 2025 -
Consultation on the search-strategy template used across the synthesis series: the databases searched, the structure of the strategy, the handling of registry records…
13 Jan 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of Maridebart cafraglutide in obesity randomising 592 participants over 52 weeks. Primary result: Mean change…
Low12 Jan 2025
page 24 of 41